GRP and prostate cancer: To improve the cancer specificity of radiolabeled TPP-derivatives targeted at the mitochondria, we have considered multifunctional 99mTc(I) tricarbonyl complexes containing the TPP moiety and a bombesin (BBN) peptide derivative that specifically recognizes the gastrin releasing peptide receptor (GRPr) overexpressed in prostate cancer cells.